23 years of historical data (2003–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Summit Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.9B | $13.1B | $12.8B | $1.6B | $822M | $248M | $327M | $53M | $115M | $898M | $644M |
| Enterprise Value | $12.7B | $12.9B | $12.7B | $1.7B | $992M | $179M | $261M | $3M | $79M | $870M | $609M |
| P/E Ratio → | -11.52 | — | — | — | — | — | — | — | 12.09 | — | — |
| P/S Ratio | — | — | — | — | 1166.67 | 137.16 | 379.96 | 85.85 | 2.03 | 51.35 | 223.76 |
| P/B Ratio | 18.83 | 19.85 | 32.99 | 20.82 | 6.49 | 2.98 | 4.11 | 0.86 | 2.05 | 64.27 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 42.77 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 42.46 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 1408.27 | 99.01 | 303.27 | 5.33 | 1.41 | 49.73 | 211.58 |
| EV / EBITDA | — | — | 728.96 | — | — | — | — | — | 10.81 | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | 8.18 | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 40.45 |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -206.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -257.0% | 100.0% | 100.0% | 77.9% | 100.0% | 99.4% | 100.0% |
| Operating Margin | — | — | — | — | -8467.0% | -4764.3% | -6185.2% | -3697.5% | 9.6% | -209.0% | -1078.6% |
| Net Profit Margin | — | — | — | — | -11185.9% | -4897.8% | -6127.6% | -3903.4% | 17.5% | -163.1% | -742.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -206.1% | -206.1% | -94.9% | -601.8% | -75.1% | -108.9% | -75.0% | -40.9% | 28.3% | -593.7% | -166.1% |
| ROA | -181.9% | -181.9% | -69.3% | -141.8% | -20.3% | -82.1% | -59.2% | -31.0% | 12.8% | -46.3% | -51.7% |
| ROIC | -163.4% | -163.4% | 0.1% | -32.9% | -28.8% | -465.4% | -314.7% | -104.7% | 132.6% | — | — |
| ROCE | -151.5% | -151.5% | 0.1% | -22.2% | -16.7% | -101.2% | -71.8% | -35.6% | 9.7% | -88.2% | -96.3% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $225M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 1.37 | 4.10 | 0.03 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | 0.41 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | -0.25 | 0.45 | 1.34 | -0.83 | -0.83 | -0.81 | -0.63 | -2.04 | — |
| Net Debt / EBITDA | — | — | -5.59 | — | — | — | — | — | -4.80 | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -2.33 |
| Interest Coverage | — | — | 0.04 | -5.45 | -13.55 | -306.71 | -208.60 | -695.65 | 8.69 | -22.18 | -28.84 |
Net cash position: cash ($225M) exceeds total debt ($21M)
Short-term solvency ratios and asset-utilisation metrics
Summit Therapeutics Inc.'s current ratio of 9.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.30x to 9.87x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.87 | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 3.34 | 6.27 | 3.63 | 1.89 | 3.06 |
| Quick Ratio | 9.87 | 9.87 | 10.15 | 9.30 | 16.93 | 3.52 | 3.93 | 6.27 | 3.63 | 1.89 | 3.05 |
| Cash Ratio | 9.77 | 9.77 | 9.88 | 9.13 | 8.99 | 2.80 | 3.34 | 5.05 | 2.09 | 1.06 | 2.58 |
| Asset Turnover | — | — | — | — | 0.00 | 0.02 | 0.01 | 0.01 | 0.72 | 0.23 | 0.06 |
| Inventory Turnover | — | — | — | — | — | — | — | 99614.74 | — | — | — |
| Days Sales Outstanding | — | — | — | — | 3169.09 | 4907.02 | 4323.55 | 3157.87 | 51.41 | 231.31 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Summit Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 8.3% | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 2.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $748M | $719M | $620M | $193M | $92M | $70M | $33M | $86M | $65M | $62M |
Compare SMMT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SMMTYou | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SMMT stacks up against sector leader BioNTech SE.
Start ComparisonSummit Therapeutics Inc.'s current P/E ratio is -11.5x. The historical average is 12.1x.
Summit Therapeutics Inc.'s return on equity (ROE) is -206.1%. The historical average is -80.8%.
Based on historical data, Summit Therapeutics Inc. is trading at a P/E of -11.5x. Compare with industry peers and growth rates for a complete picture.